Moreover, women with BC and FANCM LoF variants may benefit from poly adenosine diphosphate-ribose polymerase (PARP) inhibitors47, therefore, testing for FANCM LoF variants may identify additional therapeutic options for women with ER-negative BC. The gene discussed is FANCM; the disease is breast cancer.